|Indicated for PsO and PsA|
|Titration period||5 days||Up to 9 weeks||Up to 8 weeks|
|No label-required laboratory prescreening or ongoing monitoring*|
|Warnings and precautions||
aPregnancy category X (contraception starting 1 month before treatment and 2-year wait period after cessation to become pregnant).
*Regular monitoring is recommended for patients who are underweight at the start of treatment.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).